These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 25455776)
1. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency. Chandasana H; Prasad YD; Chhonker YS; Chaitanya TK; Mishra NN; Mitra K; Shukla PK; Bhatta RS Int J Pharm; 2014 Dec; 477(1-2):317-25. PubMed ID: 25455776 [TBL] [Abstract][Full Text] [Related]
2. Natamycin solid lipid nanoparticles - sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization. Khames A; Khaleel MA; El-Badawy MF; El-Nezhawy AOH Int J Nanomedicine; 2019; 14():2515-2531. PubMed ID: 31040672 [TBL] [Abstract][Full Text] [Related]
3. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetics studies. Bhatta RS; Chandasana H; Chhonker YS; Rathi C; Kumar D; Mitra K; Shukla PK Int J Pharm; 2012 Aug; 432(1-2):105-12. PubMed ID: 22569234 [TBL] [Abstract][Full Text] [Related]
4. Natamycin niosomes as a promising ocular nanosized delivery system with ketorolac tromethamine for dual effects for treatment of candida rabbit keratitis; in vitro/in vivo and histopathological studies. El-Nabarawi MA; Abd El Rehem RT; Teaima M; Abary M; El-Mofty HM; Khafagy MM; Lotfy NM; Salah M Drug Dev Ind Pharm; 2019 Jun; 45(6):922-936. PubMed ID: 30744431 [TBL] [Abstract][Full Text] [Related]
5. Nanomicelles empower natamycin in treating fungal keratitis: An in vitro, ex vivo and in vivo study. Sathe P; Kailasam V; Nagarjuna V; Sharma H; Velpandian T; Garg P; Nirmal J Int J Pharm; 2024 May; 656():124118. PubMed ID: 38615806 [TBL] [Abstract][Full Text] [Related]
7. Nanocubosomal based Hosny KM; Rizg WY; Alkhalidi HM; Abualsunun WA; Bakhaidar RB; Almehmady AM; Alghaith AF; Alshehri S; El Sisi AM Drug Deliv; 2021 Dec; 28(1):1836-1848. PubMed ID: 34515597 [TBL] [Abstract][Full Text] [Related]
8. Reduced administration frequency for the treatment of fungal keratitis: a sustained natamycin release from a micellar solution. Guo Y; Karimi F; Fu Q; G Qiao G; Zhang H Expert Opin Drug Deliv; 2020 Mar; 17(3):407-421. PubMed ID: 32009483 [No Abstract] [Full Text] [Related]
9. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217 [TBL] [Abstract][Full Text] [Related]
11. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. Fu T; Yi J; Lv S; Zhang B J Liposome Res; 2017 Sep; 27(3):228-233. PubMed ID: 27601177 [TBL] [Abstract][Full Text] [Related]
12. Fabrication of a drug delivery system that enhances antifungal drug corneal penetration. Li J; Li Z; Liang Z; Han L; Feng H; He S; Zhang J Drug Deliv; 2018 Nov; 25(1):938-949. PubMed ID: 29658325 [TBL] [Abstract][Full Text] [Related]
13. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial. Sharma S; Das S; Virdi A; Fernandes M; Sahu SK; Kumar Koday N; Ali MH; Garg P; Motukupally SR Br J Ophthalmol; 2015 Sep; 99(9):1190-5. PubMed ID: 25740805 [TBL] [Abstract][Full Text] [Related]
14. Bioanalytical method development and validation of natamycin in rabbit tears and its application to ocular pharmacokinetic studies. Bhatta RS; Chandasana H; Rathi C; Kumar D; Chhonker YS; Jain GK J Pharm Biomed Anal; 2011 Apr; 54(5):1096-100. PubMed ID: 21168297 [TBL] [Abstract][Full Text] [Related]
15. Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics. Mascarenhas M; Chaudhari P; Lewis SA Adv Ther; 2023 Aug; 40(8):3332-3359. PubMed ID: 37289410 [TBL] [Abstract][Full Text] [Related]
16. Niosomes: Do They Increase the Potency of Topical Natamycin Ketorolac Formula in Treating Aspergillus Keratitis? An Experimental Study. El-Mofty HM; El-Nabarawi MA; Abd El Rehem RT; Teaima MH; Abary MYS; Salah M; Lotfy NM J Ocul Pharmacol Ther; 2020 Sep; 36(7):545-554. PubMed ID: 32357092 [No Abstract] [Full Text] [Related]
17. Thermosensitive Tri-Block Polymer Nanoparticle-Hydrogel Composites as Payloads of Natamycin for Antifungal Therapy Against Sha X; Chan L; Fan X; Guo P; Chen T; Liu L; Zhong J Int J Nanomedicine; 2022; 17():1463-1478. PubMed ID: 35378880 [TBL] [Abstract][Full Text] [Related]
18. Formulation Development, Optimization, and In Vitro-In Vivo Characterization of Natamycin-Loaded PEGylated Nano-Lipid Carriers for Ocular Applications. Patil A; Lakhani P; Taskar P; Wu KW; Sweeney C; Avula B; Wang YH; Khan IA; Majumdar S J Pharm Sci; 2018 Aug; 107(8):2160-2171. PubMed ID: 29698725 [TBL] [Abstract][Full Text] [Related]
19. In vitro uptake and release of natamycin from conventional and silicone hydrogel contact lens materials. Phan CM; Subbaraman LN; Jones L Eye Contact Lens; 2013 Mar; 39(2):162-8. PubMed ID: 23392304 [TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis. Sharma N; Chacko J; Velpandian T; Titiyal JS; Sinha R; Satpathy G; Tandon R; Vajpayee RB Ophthalmology; 2013 Apr; 120(4):677-81. PubMed ID: 23246119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]